- Market Capitalization, $K 6,251,245
- Shares Outstanding, K 357,214
- Annual Sales, $ 229,210 K
- Annual Income, $ -116,450 K
- 60-Month Beta 1.07
- Price/Sales 15.94
- Price/Cash Flow N/A
- Price/Book 10.94
|Period||Period Low||Period High||Performance|
| || |
-4.00 (-19.78%)since 01/24/20
| || |
-4.25 (-20.76%)since 11/26/19
| || |
-3.79 (-18.94%)since 02/26/19
Amarin's (AMRN) strong revenue growth in the fourth quarter is driven by solid demand for its cardiovascular drug, Vascepa.
Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at two upcoming investor conferences....
Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and full year 2019 financial results...
Various reports concerning the electrophysiology markets project that the market and its segments will continue to experience substantial growth in the coming years. Electrophysiology is the biomedical...
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin Corporation plc (NASDAQ:AMRN), announced today that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication for VASCEPA(R) (icosapent ethyl) by the U.S. Food...
Amarin (AMRN) closed the most recent trading day at $18.72, moving -0.58% from the previous trading session.
In the latest trading session, Amarin (AMRN) closed at $19.04, marking a -1.4% move from the previous day.
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, is pleased to update investors that Vascepa(®)...
|Amarin Corp Ads|
|Pharmaceutical Vaneck ETF|
|GS Hedge Industry Vip ETF|
|Nasdaq Biotechnology Ishares ETF|
|Bldrs Europe Select ADR Index Fund Invesco|
|Bldrs Developed Markets 100 ADR Index Fund Inves|